Long-term survival of patients with Hodgkin's disease. Treatment with cyclophosphamide, vinblastine, procarbazine, and prednisone

Publisher Website
Google Scholar
Abstract
Thirty-eight patients with advanced Hodgkin''s disease were treated with a combination of cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP). The minimum period of observation for surviving patients was 5 yr. Twenty-eight patients (74%) achieved complete remission; in 17 (61%) remissions lasted at least 5 yr. Twenty-five (66%) of the 38 patients survived more than 5 yr from the initiation of CVPP. There were no differences in rates or duration of response when evaluation was performed for multiple pretreatment clinical features. Survival was adversely influenced by advanced age, nodular sclerosis histologic subtype and pretreatment bone marrow involvement. Two patients died in remission of overwhelming viral infections; acute nonlymphocytic leukemia developed in 1 patient. In another patient, aseptic necrosis of the heads of both femora developed. Treatment with CVPP may result in long-term disease-free survival for patients with advanced Hodgkin''s disease.

This publication has 2 references indexed in Scilit: